Your session is about to expire
← Back to Search
Tofacitinib for Lupus
Study Summary
This trial will test if the drug Tofacitinib can help treat people with Lupus.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 209 Patients • NCT02281552Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of keloid scarring.I am not taking ketoconazole or similar medications.I have had cancer or lymph-related disorders before.I do not have any uncontrolled serious diseases.I have a history of HIV, hepatitis B, or hepatitis C.I have a long-term lung disease.I have an autoimmune disease that needs treatment to lower my immune system.I have a history of serious heart artery disease.I am fully vaccinated against COVID-19 as per CDC guidelines.I might have a kidney infection or a urinary tract infection.I have had serious stomach or intestine problems.I am between 18 and 65 years old.I am taking, or have recently taken, specific medications.I have received vaccines that are not live.I have received specific previous treatments.I have not taken any corticosteroids through injection or IV in the last 2 weeks.I have a history of chronic infections or was recently exposed to tuberculosis.I have a record of all my vaccinations, including any live vaccines.I have been diagnosed with cutaneous lupus by a specialist.I have not had any active skin conditions in the last 5 years.I have not had major surgery or been hospitalized for a serious infection recently.I have had blood clots, a pulmonary embolism, or antiphospholipid syndrome.I am on specific doses of certain medications like corticosteroids or methotrexate.
- Group 1: Tofacinitib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree are individuals qualified to participate in this research?
"To be eligible for this medical trial, subjects need to have barrett esophagus and be between 18 years old and 65. Currently, 10 patients are being sought out for enrollment."
What ailment is Tofacitinib usually prescribed to alleviate?
"Tofacitinib is frequently prescribed to help control symptoms of juvenile arthritis. It can also be beneficial for patients who cannot tolerate methotrexate, have a lacklustre response to conventional treatment protocols, or are unresponsive to methotrexate."
Is the recruiting phase of this trial still active?
"Indeed, the study is actively recruiting patients according to clinicaltrials.gov. The initial posting date was March 23rd 2022 with updated information shared on May 2nd 2022."
Have other experiments focused on the use of Tofacitinib for medical purposes?
"Currently, 34 clinical trials revolving around Tofacitinib are in progress with 7 of those being at the advanced Phase 3 stage. The majority of these studies take place in Shanghai but there exist 662 other sites conducting research on this drug."
What is the size of this medical research's participant pool?
"Affirmative. According to the clinicaltrials.gov records, this research project is currently searching for participants; moreover it was initially published on March 23rd 2022 and recently updated on May 2nd 2022. The trial needs 10 patients at two distinct sites for enrollment."
Is this investigation enrolling individuals aged 55 or older?
"This study is enrolling individuals aged 18 years and above, but below the age of 65."
Is Tofacitinib a reliable and secure medication for patients?
"There is limited clinical evidence backing the safety and efficacy of Tofacitinib, which earns it a score of 1."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger